Overview

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients With ACC- an Open, Non-commercial Clinical Trial

Status:
Not yet recruiting

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

Non-commercial phase 2 clinical trial to evaluate the effectiveness, safety and tolerability of treatment using prostate-specific membrane antigen (PSMA) labeled with 177Lutetium in patients with recurrence and/or metastases in adenoid cystic carcinoma originating from the salivary glands of the head and neck region. Patients with PSMA receptor expression confirmed by PET/CT after administration of 68Ga-PSMA I&T will be eligible for treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Maria Sklodowska-Curie National Research Institute of Oncology

Treatments:

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid